Some areas of AAO.org are temporarily unavailable. We apologize for the inconvenience and are working to restore access.

  •   
    By Dan S. Gombos, MD, FACS; Carol L. Shields, MD
    AAO 2015
    Childhood Malignancies, Ocular Pathology/Oncology, Pediatric Ophth/Strabismus, Vitreoretinal Diseases

    In this interview from AAO 2015, Dr. Carol Shields discusses the latest advances in treating vitreous disease in retinoblastoma. She offers tips for safely injecting melphalan, and reviews safe dosage levels. Additionally, she discusses the need for genetic testing in all patients with retinoblastoma and subsequent surveillance. Low-risk patients, those with a sibling with unilateral retinoblastoma, should be seen at 2 weeks, and at 2, 6 and 12 months, while high-risk patients should be seen at the same time points, and at 4 and 9 months.